Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome)

European Journal of Paediatric Neurology

Volumn 6, Issue 5, 2002, Pages 243-247

  Gordon, Neil ^a  

^a Huntlywood   (United Kingdom)

Author keywords

Causes; Nomenclature; PKAN; Symptoms; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIOXIDANT; BACLOFEN; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; COENZYME A; CYSTEINE; IRON; LEVODOPA; PANTOTHENATE KINASE; PANTOTHENIC ACID;

ADULTHOOD; AUTOPSY; BASAL GANGLION; BRAIN DEGENERATION; CHROMOSOME 20; DEATH; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DISABILITY; DISEASE COURSE; DYSARTHRIA; DYSTONIA; ENERGY METABOLISM; EPILEPSY; ETHICS; FATTY ACID SYNTHESIS; GENE INDUCTION; HALLERVORDEN SPATZ DISEASE; HUMAN; INFANCY; INVOLUNTARY MOVEMENT; NERVE FIBER; NEUROAXONAL DYSTROPHY; NOMENCLATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OXIDATIVE STRESS; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SPASTICITY; SYMPTOMATOLOGY; TISSUE INJURY; VITAMIN METABOLISM;

EID: 0037000025     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejpn.2002.0606     Document Type: Review

References (48)

1. Harper P. Naming of syndromes and unethical activities: the case of Hallervorden and Spatz. Lancet 1996; 348: 1224-1225.
2. Shevell MI, Peiffer J. Julius Hallervorden's wartime activities: implication for science under dictatorship. Pediatr Neurol 2001; 25: 162-165.
3. Morrison P. Naming of syndromes. Lancet 1996; 348: 1662.
4. Shevell M. Naming of syndromes. Lancet 1996; 348: 1662.
5. Jacby R, Oppenheimer C. Naming of syndromes. Lancet 1996; 348: 1662.
6. Vaher U, Napa A, Nurmiste A et al. Four siblings with Hallervorden-Spatz disease. Brain Dev 2001; 23: 236-239.
7. Zhou B, Westaway SK, Levinson B et al. A novel pantothenate kinase gene is defective in Hallervorden-Spatz syndrome. Nature Genet 2001; 28: 345-349.
8. Halliday W. The nosology of Hallervorden-Spatz disease. J Neurol Sci 1995; 134: 84-91.
9. Peña JA, Molina O, Cardozo J. Hallervorden-Spatz disease: two new early childhood onset cases. J Child Neurol 2000; 15: 30-32.
10. Østergaard JR, Christensen T, Hansen KN. In vivo diagnosis of Hallervorden-Spatz disease. Dev Med Child Neurol 1995; 37: 827-833.
11. Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 2000; 69: 392-395.
12. Nardocci N, Rumi, V Angelini L et al. Complex tics, stereotypes, and compulsive behaviour as clinical presentation of a juvenile progressive dystonia suggestive of Hallervorden-Spatz disease. Mov Disord 1994; 9: 369-371.
13. Casteels I, Spileers W, Swinnen T et al. Optic atrophy as the presenting sign in Hallervorden-Spatz syndrome. Neuropediatrics 1994; 25: 265-267.
14. Battistella PA, Midena E, Suppiej A, Carollo C. Optic atrophy as the first symptom in Hallervorden-Spatz syndrome. Childs Nerv Syst 1998; 14: 135-138.
15. Muthane UB, Shetty R, Panda K et al. Hallervorden Spatz disease and acanthocytes. Neurology 1999; 53: 32A.
16. Malandrini A, Bonuccelli U, Parrotta E et al. Myopathic involvement in two cases of Hallervorden-Spatz disease. Brain Dev 1995; 17: 286-290.
17. Suri M. What's new in neurogenetics? Focus on neurodegenerative disorders. Eur J Paediatr Neurol 2001; 5: 221-224.
18. Hickman SJ, Ward NS, Surtees RAH, Stevens JM, Farmer SF. How broad is the phenotype of Hallervorden-Spatz disease? Acta Neurol Scand 2001; 103: 201-203.
19. Trussart V, Lebouco N, Carlander B, Billiard M, Castan P. Syndrome de Hallervorden-Spatz et IRM: 'l'oeil du tigre'. J Neuroradiol 1993; 20: 70-75.
20. Guillerman RP. The eye-of-the-tiger sign. Radiology 2000; 217: 895-896.
21. Hermann W, Barthel H, Reuter M, et al. Constellation of findings on nigrostriatal system in case of Hallervorden-Spatz disease. Nervenarzt 2000; 71: 660-665.
22. Müller T, Amoiridis G, Kuhn W, Przuntek H. Iron deposits in the subthalamic nuclei in Hallervorden-Spatz disease. Eur Neurol 1999; 42: 240-241.
23. Hayflick S, Penzien JM, Michl W et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 166-169.
24. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 148-155.
25. Wakabayashi K, Fukushima T, Koide R et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol 2000; 99: 331-336.
26. Sodeyama N, Arai M, Sanjoh N, Orimo S, Tamaki M. A case of Hallervorden-Spatz syndrome with marked atrophy of the brainstem and cerebellum. Rinsho Shinkeigaku 1993; 33: 525-529.
27. Schwerin A, Peak D, Green SH, Chapman S. Hallervorden-Spatz syndrome in four children. Dev Med Child Neurol 2001; 43 (Suppl 90): 19.
28. Taylor TD, Litt M, Kramer P et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p 12.3-p13. Nature Genet 1996; 14: 479-481.
29. Shoham S, Youdim MBH. Iron involvement in neural danage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 2000; 46: 743-760.
30. Hayflick SJ. First scientific workshop on Hallervorden-Spatz syndrome: Executive summary. Pediatr Neurol 2001; 25: 99-101.
31. Gordon N. Friedreich's ataxia and iron metabolism. Brain Dev 2000; 22: 465-468.
32. Gordon N. Hereditary vitamin-E deficiency. Dev Med Child Neurol 2001; 43: 133-135.
33. Neumann M, Adler S, Schlüter O et al. α-Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formally Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol 2000; 100: 568-574.
34. Galvin JE, Giasson B, Hurtig HI, Lee MV-Y, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by α- β-and γ-synuclein neuropathology. Am J Pathol 2000; 157: 361-368.
35. Sastry S, Arendash GW. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience 1995; 67: 649-666.
36. Nishiyama K, Murayama S, Nishimura Y, Asayama K, Kanazawa I. Superoxide dismutase-like immunoreactivity in spheroids in Hallervorden-Spatz disease. Acta Neuropathol 1997; 93: 19-23.
37. Simonati A, Trevisan C, Salviati A, Rizzuto N. Neuroaxonal dystrophy with dystonia and pallidal involvement. Neuropediatrics 1999; 30: 151-154.
38. Malandrini A, Cavallaro T, Fabrizi GM et al. Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden-Spatz disease and infantile neuroaxonal dystrophy. Virchows Arch 1995; 427: 415-421.
39. Senior K. New genes reveal major role for iron in neurodegeneration. Lancet 2001; 358: 302.
40. Singhi P,Mitra S. Hallervorden-Spatz disease: late infantile type. J Child Neurol 1997; 12: 280-282.
41. Albright AL, Barry MJ, Fasick P, Barron W, Shultz B. Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 1996; 38: 934-939.
42. Diego MR, Garcia JN. Enfermedad de Hallervorden-Spatz y toxina botulinica. An Esp Pediatr 1997; 47: 443-444.
43. Justesen CR, Penn RD, Kroin JS, Egel RT. Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. J Neurosurg 90: 551-554.
44. Keegan MT, Flick RP, Matsumoto JY, Davis DH, Lanier WL. Anesthetic management for two-stage computer-assisted, stereotactic thalamotomy in a child with Hallervorden-Spatz disease. J Neurosurg Anesthesiol 2000; 12: 107-111.
45. Dressler D, Wittstock M, Benecke R. Botulinium toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome. Eur Neurol 2001; 45: 287-288.
46. Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 102-108.
47. Sheehy EC, Longhurst P, Pool D, Dandekar M. Self-inflicted injury in a case of Hallervorden-Spatz disease. Int J Paediatr Dent 1999; 9: 299-302.
48. Chiuch CC. Iron overload, oxidative stress, and axonal dystrophy in brain disorders. Pediatr Neurol 2001; 25: 138-147.